stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

4D Molecular Therapeutics, Inc.

United States · NASDAQ: FDMT · Market cap: · P/E: · P/S:

4D Molecular Therapeutics develops gene therapy medicines designed to treat eye, lung, and heart diseases.

4D Molecular Therapeutics is a gene therapy company. It builds medicines that deliver a working copy of a gene into a patient's cells, so the body can make a missing or broken protein itself. The company focuses on three areas: eye diseases, lung diseases, and heart diseases.

The core technology is a library of engineered viruses, called vectors, that act as delivery trucks. A virus is naturally good at getting inside cells, so scientists strip out the parts that cause disease and load in a therapeutic gene instead. 4D's twist is that it designs these vectors from scratch and tests huge numbers of them to find ones that reach a specific tissue — say, the retina or the lung — when injected in a simple way. That matters because older gene therapies often required surgery or risky high doses. If a vector can be given as an ordinary injection and still reach the right cells, treatment becomes safer and easier. Its lead programs target wet age-related macular degeneration and diabetic macular edema, two common causes of vision loss, using a vector injected into the eye. It is also developing inhaled treatments for lung diseases such as cystic fibrosis and a heart treatment for a genetic condition that causes heart failure. The company earns no product revenue yet; it funds itself through stock sales, partnerships, and licensing deals while its candidates move through clinical trials. That is the central risk and the central bet: gene therapy is expensive to develop, trials can fail, and regulators must be convinced the treatments are safe.


The field is crowded and volatile. Competitors include Spark Therapeutics-style gene therapy pioneers and larger players such as Novartis and Regeneron, which already sell eye drugs that 4D hopes to replace with one-time treatments. Success depends on clinical data and on manufacturing enough vector reliably. Investors are essentially paying for a pipeline of experiments, so the stock swings hard on trial results.

Saved answer · last researched 16 Nov 2026